Biotime Newswire

Biotime Newswire

Comprehensive Real-Time News Feed for Biotime.

Results 1 - 20 of 103 in Biotime

  1. BioTime, Inc. (BTX) Director Broadwood Partners Lp Buys 2,732,636 SharesRead the original story w/Photo

    Friday Jun 24 | Daily Political

    BioTime, Inc. Director Broadwood Partners Lp bought 2,732,636 shares of the stock in a transaction dated Tuesday, June 21st. The shares were purchased at an average cost of $2.39 per share, for a total transaction of $6,531,000.04.

    Comment?

  2. BioTime, Inc. (BTX) Director Purchases $6,531,000.04 in StockRead the original story w/Photo

    Thursday Jun 23 | AmericanBankingNews.com

    BioTime, Inc. Director Broadwood Partners Lp purchased 2,732,636 shares of the stock in a transaction dated Tuesday, June 21st. The stock was purchased at an average price of $2.39 per share, with a total value of $6,531,000.04.

    Comment?

  3. BioTime Announces Closing Of Public Offering Of Common StockRead the original story

    Monday Jun 20 | BioSpace

    BioTime, Inc. , a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the closing of its previously announced underwritten public offering. BioTime, Inc. sold 7,322,176 shares of its common stock in the offering.

    Comment?

  4. A Look at Five Stocks that Are Trending on ThursdayRead the original story w/Photo

    Thursday Jun 16 | Insider Monkey

    ... Group PLC (ADR) (NYSE: LYG ), Wal-Mart Stores, Inc. (NYSE: WMT ), AMC Entertainment Holdings Inc (NYSE: AMC ) and BioTime, Inc. (NYSEMKT: BTX ). In this article, we will take a look at the reasons behind the movement of these stocks today and see ...

    Comment?

  5. BioTime, Inc. Announces Pricing of Public Offering of Common StockRead the original story w/Photo

    Thursday Jun 16 | Freshnews

    BioTime, Inc. , a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced the pricing of an underwritten public offering of 7,322,176 shares of its common stock at a public offering price of $2.39 per share. The gross proceeds to BioTime, Inc. from this offering are expected to be approximately $17.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by BioTime, Inc. The offering is expected to close on or about June 21, 2016, subject to customary closing conditions.

    Comment?

  6. BRIEF-Biotime says public offering of 7.32 mln common shares priced at $2.39 per shareRead the original story w/Photo

    Thursday Jun 16 | Reuters

    * Biotime Inc. Announces pricing of public offering of common stock Source text for Eikon: Further company coverage: (Bengaluru Newsroom; +1 646 223 8780) New cancer therapies are proving successful but they're pricey at over $100,000 a year. Expect a clash between payers and drugmakers.

    Comment?

  7. BioTime Announces Proposed Public Offering Of Common StockRead the original story

    Wednesday Jun 15 | BioSpace

    BioTime, Inc. , a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Comment?

  8. BioTime, Inc. Announces Proposed Public Offering of Common StockRead the original story w/Photo

    Wednesday Jun 15 | Freshnews

    BioTime, Inc. , a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine, today announced its intent to offer to sell shares of its common stock in an underwritten public offering. The offering is subject to market, regulatory and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

    Comment?

  9. BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval...Read the original story

    Monday Jun 13 | Information Technology

    BioTime, Inc. and Cell Cure Neurosciences Ltd. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board , an independent group of medical experts closely monitoring the clinical trial, has reviewed the initial safety data from the first cohort in the Phase I/IIa clinical trial of OpRegen . OpRegen is comprised of retinal pigment epithelial cells designed for the treatment of the advanced form of dry age-related macular degeneration .

    Comment?

  10. BioTime??'s Subsidiary Receives DSMB Approval To Start Second Patient ...Read the original story

    Sunday Jun 12 | BioSpace

    BioTime 's Subsidiary Cell Cure Neurosciences Receives DSMB Approval To Start Second Patient Cohort In Clinical Trial For Dry-AMD ALAMEDA, Calif. & JERUSALEM-- --BioTime, Inc. and Cell Cure Neurosciences Ltd. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board , an independent group of medical experts closely monitoring the clinical trial, has reviewed the initial safety data from the first cohort in the Phase I/IIa clinical trial of OpRegen A .

    Comment?

  11. BioTime's Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort...Read the original story w/Photo

    Monday Jun 13 | Freshnews

    BioTime, Inc. and Cell Cure Neurosciences Ltd. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the Data Safety Monitoring Board , an independent group of medical experts closely monitoring the clinical trial, has reviewed the initial safety data from the first cohort in the Phase I/IIa clinical trial of OpRegen A . OpRegenA is comprised of retinal pigment epithelial cells designed for the treatment of the advanced form of dry age-related macular degeneration .

    Comment?

  12. BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD ProgramRead the original story

    Friday Jun 10 | Information Technology

    BioTime, Inc. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, and its subsidiary Cell Cure Neurosciences Ltd. today announced that Cell Cure has been awarded a new grant for 2016 of 8.4 million shekels from the Israel Innovation Authority of the Ministry of Economy and Industry. The grant provides continuing funding for the development of OpRegen , a cell-based therapeutic product that consists of animal product-free retinal pigment epithelial cells with high purity and potency.

    Comment?

  13. BioTime to Present at the Jefferies 2016 Global Healthcare ConferenceRead the original story w/Photo

    Thursday Jun 9 | Freshnews

    BioTime, Inc. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today announced that the company will present at the Jefferies 2016 Global Healthcare Conference to be held in New York on June 7-10, 2016. Russell Skibsted, BioTime's Chief Financial Officer, will provide an overview and an update on product development at 1:30 PM EDT on Friday, June 10, 2016.

    Comment?

  14. BioTime, Inc. (BTX) Shares Bought by BlackRock Group LTDRead the original story w/Photo

    Sunday May 29 | Daily Political

    BlackRock Group LTD boosted its stake in BioTime, Inc. by 596.6% during the first quarter, Holdings Channel reports. The fund owned 37,580 shares of the company's stock after buying an additional 32,185 shares during the period.

    Comment?

  15. BioTime, Inc. (BTX) Short Interest Down 1.3% in MayRead the original story w/Photo

    May 25, 2016 | AmericanBankingNews.com

    BioTime, Inc. saw a large decrease in short interest during the month of May. As of May 13th, there was short interest totalling 7,830,461 shares, a decrease of 1.3% from the April 29th total of 7,933,316 shares. Currently, 9.0% of the company's shares are sold short.

    Comment?

  16. BioTime To Present At Two Upcoming Investor ConferencesRead the original story

    May 22, 2016 | BioSpace

    BioTime, Inc. announced that Co-Chief Executive Officer Michael D. West, Ph.D., will present at the 2016 Oppenheimer 17th Annual Israel Conference to be held at the David Intercontinental Hotel in Tel-Aviv on Sunday, May 22, 2016. Dr. West will also present at the Mauldin Economics 2016 Strategic Investment Conference, in Dallas, Texas on May 25, 2016.

    Comment?

  17. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    May 20, 2016 | Business Wire

    The bonds, which will finance con... )--Fitch Ratings has assigned a 'AA-' rating for the following Commonwealth of Pennsylvania's general obligation bonds: --$355 million first series of 2016; --$635.55 m... )--Andrew Stranberg, CEO and Chairman of STRAN & COMPANY, INC, announced today his intention to commence a cash tender offer to the shareholders of Swisher Hygiene Inc. --Following its peer review of the Panamanian midsized banks, Fitch Ratings has taken rating actions on the following entities: --Banco Aliado, S.A.; --Ban... )--BioTime, Inc. announced that Co-Chief Executive Officer Michael D. West, Ph.D., will present at the 2016 Oppenheimer 17th Annual Israel Co... )--Fitch Ratings assigns the following ratings to Evergreen Credit Card Trust, series 2016-1: --$1,000,000,000 USD class A asset-backed notes 'AAAsf'; Outlook Stable; --$55,... )--Bemis Company, Inc. has been selected ... (more)

    Comment?

  18. Oppenheimer Research Analysts Lift Earnings Estimates for BioTime, Inc.Read the original story w/Photo

    May 21, 2016 | Daily Political

    Analysts at Oppenheimer lifted their Q3 2016 earnings per share estimates for BioTime in a report issued on Wednesday, Zacks Investment Research reports. Oppenheimer analyst L. Wang now forecasts that the firm will earn per share for the quarter, up from their previous forecast of .

    Comment?

  19. BioTime Reports First Quarter Results And Recent Corporate AccomplishmentsRead the original story

    May 10, 2016 | BioSpace

    BioTime, Inc. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and provided a corporate update. The Company also announced that management will host a conference call with investors to discuss the recent operating progress and corporate developments on Tuesday, May 17, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

    Comment?

  20. BioTime, Inc. Reports First Quarter Results and Recent Corporate AccomplishmentsRead the original story

    May 10, 2016 | Information Technology

    BioTime, Inc. , a clinical-stage regenerative medicine company with a focus on pluripotent stem cell technology, today reported financial results for the first quarter ended March 31, 2016 and provided a corporate update. The Company also announced that management will host a conference call with investors to discuss the recent operating progress and corporate developments on Tuesday, May 17, 2016 at 4:30 p.m. Eastern / 1:30 p.m. Pacific.

    Comment?